

# Vaccines and Global Health: The Week in Review 23 June 2018 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is also **posted in pdf form** and as a set of blog posts at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full-text searching of over 8,000 entries. Comments and suggestions should be directed to

David R. Curry, MS

Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

**Request an email version:** Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening at midnight (EST/U.S.). If you would like to receive the email version, please send your request to <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

**Contents** [click on link below to move to associated content]

A. Milestones :: Perspectives :: Featured Journal Content

B. Emergencies

C. WHO; CDC [U.S., Africa, China]

D. Announcements

E. Reports/Research/Analysis

E. Journal Watch

F. Media Watch

**Milestones :: Perspectives** 

::::::

## Ebola/EVD

## **EBOLA VIRUS DISEASE – Democratic Republic of the Congo**

External Situation Report 12: 22 June 2018

The Ministry of Health and WHO continue to closely monitor the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo. Over one month into the response, further spread of EVD has largely been contained. However, in spite of the progress made, there should be no room for laxity and complacency until the outbreak is controlled. The focus of the response remains on intensive surveillance, including active case finding, investigation of suspected cases and alerts and contact tracing.

On 20 June 2018, four new suspected EVD cases were reported in Iboko (2) and Bikoro (2) health zones. Four laboratory specimens (from suspected cases reported previously) tested negative. Since 17 May 2018, no new confirmed EVD cases have been reported in Bikoro and Wangata health zones, while the last confirmed casepatient in Iboko Health Zone developed symptoms on 2 June 2018, was confirmed on 6 June 2018 and died on 9 June 2018. Since the beginning of the outbreak (on 4 April 2018), a total of 61 EVD cases and 28 deaths have been reported, as of 20 June 2018. Of the 61 cases, 38 have been laboratory confirmed, 14 were probable cases (deaths for which it was not possible to collect laboratory specimens for testing) and nine were suspected cases. Of the 52 confirmed and probable cases, 28 died – giving a case fatality rate of 54%. Twenty-seven (52%) confirmed and probable cases were from Iboko, followed by 21 (40%) from Bikoro and four (8%) from Wangata health zones. Five healthcare workers have been affected, with four confirmed cases and two deaths.

The number of contacts requiring follow-up is progressively decreasing, with a total of 1 527 contacts having completed the mandatory 21-day follow-up period. As of 20 June 2018, 179 contacts were under follow up and all (100%) were reached on the reporting date...

#### [Excerpts]

## Implementation of ring vaccination protocol

Since the launch of the vaccination exercise on 21 May 2018, a total of 3 199 people have been vaccinated in Iboko (1 464) Wangata (836), Bikoro (779), Ingende (107), and Kinshasa (13), as of 21 June 2018. The targets for vaccination are front-line health professionals, people who have been exposed to confirmed EVD cases and contacts of these contacts...

#### Case management

WHO is providing technical advice on the use of investigational therapeutics under the Monitored Emergency Use of Unregistered Interventions (MEURI) framework and provision of essential medical supplies. Four of the five investigational therapeutics are in-country and all protocols have been approved by the Ethics Review Board (ERB). This is the first time such treatments have been available during an Ebola outbreak. Clinicians working in the treatment centres will make decisions on which drug will be most helpful to their patients, and appropriate for the setting. The treatments can be used as long as informed consent is obtained from patients and protocols are followed, with close monitoring and reporting of any adverse events.

Four of the five approved drugs are currently in the country. They are Zmapp, GS-5734, REGN monoclonal antibody combination, and mAb114...

Disease Outbreak News [DONs] 20 June 2018

## **Ebola virus disease – Democratic Republic of the Congo**

The Ministry of Health and WHO continue to closely monitor the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo. There is cautious optimism. Slightly over a month into the response, further spread of EVD has largely been contained. However, in spite of progress, there should be no room for laxity and complacency until the outbreak is controlled. The focus of operations remains on intensive surveillance and active case finding.

Since 17 May 2018, no new confirmed EVD cases have been reported in Bikoro and Wangata health zones, while the last confirmed case-patient in Iboko developed symptoms on 2 June 2018 and died on 9 June...

::::::

## WHO releases new International Classification of Diseases (ICD 11)

18 June 2018 | Geneva: The World Health Organization (WHO) is today releasing its new International Classification of Diseases (ICD-11).

The ICD is the foundation for identifying health trends and statistics worldwide, and contains around 55,000 unique codes for injuries, diseases and causes of death. It provides a common language that allows health professionals to share health information across the globe.

"The ICD is a product that WHO is truly proud of," says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "It enables us to understand so much about what makes people get sick and die, and to take action to prevent suffering and save lives."

ICD-11, which has been over a decade in the making, provides significant improvements on previous versions. For the first time, it is completely electronic and has a much more user-friendly format. And there has been unprecedented involvement of health care workers who have joined collaborative meetings and submitted proposals. The ICD team in WHO headquarters has received over 10 000 proposals for revisions.

ICD-11 will be presented at the World Health Assembly in May 2019 for adoption by Member States, and will come into effect on 1 January 2022. This release is an advance preview that will allow countries to plan how to use the new version, prepare translations, and train health professionals all over the country.

The ICD is also used by health insurers whose reimbursements depend on ICD coding; national health programme managers; data collection specialists; and others who track progress in global health and determine the allocation of health resources.

The new ICD-11 also reflects progress in medicine and advances in scientific understanding. For example, the codes relating to antimicrobial resistance are more closely in line with the Global

Antimicrobial Resistance Surveillance System (GLASS). ICD-11 is also able to better capture data regarding safety in healthcare, which means that unnecessary events that may harm health – such as unsafe workflows in hospitals - can be identified and reduced.

The new ICD also includes new chapters, one on traditional medicine: although millions of people use traditional medicine worldwide, it has never been classified in this system. Another new chapter on sexual health brings together conditions that were previously categorized in other ways (e.g. gender incongruence was listed under mental health conditions) or described differently. Gaming disorder has been added to the section on addictive disorders...

:: ICD website

:: ICD-11 coding too

::::::

### **Emergencies**

#### **POLIO**

**Public Health Emergency of International Concern (PHEIC) Polio this week as of 19 June 2018** [GPEI]

- :: Advance notification of cVDPV1 in Papua New Guinea: Following identification last month of an AFP case from which VDPV type 1 had been isolated, genetic sequencing of two VDPV1s from two non-household contacts of the AFP case, has now confirmed that VDPV1 is circulating and will be officially classified as a 'circulating' VDPV type 1 (cVDPV1). The National Department of Health (NDOH) is closely working with the GPEI partners in launching a comprehensive response. The cVDPV1 will be officially reported in next week's data.
- :: **Advance notification of new cVDPV2 in DR Congo**: Advance notification of a new cVDPV2 case was received this week from Ituri province, in the north-east of DR Congo, close to the border with Uganda. Initial investigations are ongoing, but early reports are that the child had onset of paralysis on 5 May 2018, and has a recent travel history with Haut Katanga. Genetic sequencing indicates the case is linked to the Haut Lomami/Tanganika/Haut Katanga outbreak. The case will be officially reported in next week's data.

Summary of newly-reported viruses this week:

**Pakistan:** Three wild poliovirus type 1 (WPV1) positive environmental samples reported **Afghanistan:** Two wild poliovirus type 1 (WPV1) positive environmental samples reported **Somalia**: One circulating vaccine-derived poliovirus type 2 (cVDPV2) environmental sample reported

::::::

## WHO Grade 3 Emergencies [to 23 Jun 2018]

#### Yemen

:: WHO continues life-saving support to Yemen's blood transfusion centres

On the occasion of World Blood Donor Day 2018, WHO reaffirms the need of having an adequate blood supply to meet the needs of patients14 June 2018 – It has been over 3 years since Yemen was hit by one of the world's worst humanitarian crises. The crisis has worsened

an already the appalling health situation. Conditions in the blood transfusion centres across the country are no different, further aggravated by the ongoing conflict and facing the threat of closure due to shortages in essential blood bags and reagents.

WHO is working hard to prevent the closure of these centres, scaling up support for the supply of safe blood products in Yemen. In 2017–2018, WHO provided over 130 000 blood bags and various types of laboratory reagents to the national blood transfusion centre, maintained the provision of services in Sana'a, and helped in re-opening the other branches in Ibb, Hudydah and Aden...

<u>Iraq</u> - No new announcements identified <u>Nigeria</u> - No new announcements identified <u>South Sudan</u> - Webpage not responding at inquiry The Syrian Arab Republic - No new announcements identified

::::::

## WHO Grade 2 Emergencies [to 23 Jun 2018]

[Several emergency pages were not available at inquiry]

<u>Cameroon</u> - No new announcements identified

Central African Republic - No new announcements identified.

Democratic Republic of the Congo - No new announcements identified

Ethiopia - No new announcements identified.

Libya - No new announcements identified.

Myanmar - No new announcements identified

Niger - No new announcements identified.

Ukraine - No new announcements identified.

::::::

#### **UN OCHA – L3 Emergencies**

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

#### Yemen

- :: Yemen: Al Hudaydah Update Situation Report No. 4, 22 June 2018 HIGHLIGHTS/KEY PRIORITIES
- :: Fighting and airstrikes are continuing in Al Hudaydah City and in southern districts. Casualties are reported.
- :: More people are fleeing areas of conflict and seeking shelter in safer locations, including in the capital, Sana'a
- :: IDPs from Al Hudaydah City have arrived in the capital, Sana'a. Total figures on displacement are not available yet as humanitarian organisations are verifying the IDPS.
- :: Humanitarian partners have ramped up rapid response activities amid security and access constraints

Syrian Arab Republic - No new announcements identified.

::::::

#### **UN OCHA – Corporate Emergencies**

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

#### **Ethiopia**

- :: Ethiopia Humanitarian Bulletin Issue 55 | 4 17 June 2018
- :: <u>Ethiopia</u>: <u>Oromia Somali Conflict-Induced Displacement Situation Report No. 4 (20 June 2018)</u>

Somalia - No new announcements identified.

::::::

#### Editor's Note:

We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

### **EBOLA/EVD** [to 23 Jun 2018]

http://www.who.int/ebola/en/ [See Milestones above for detail]

## **MERS-CoV** [to 23 Jun 2018]

http://who.int/emergencies/mers-cov/en/

**DONs** 

## <u>Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia</u>

18 June 2018

Between 12 January through 31 May 2018, the National IHR Focal Point of The Kingdom of Saudi Arabia reported 75 laboratory confirmed cases of Middle East respiratory syndrome coronavirus (MERS\_CoV), including twenty-three (23) deaths...

#### Yellow Fever [to 23 Jun 2018]

http://www.who.int/csr/disease/yellowfev/en/

- No new announcements identified.

#### Zika virus [to 23 Jun 2018]

http://www.who.int/csr/disease/zika/en/

- No new announcements identified.

::::::

#### WHO & Regional Offices [to 23 Jun 2018]

<u>Paediatric chewable medicine promises improved treatment against intestinal worms</u>

20 June 2018 | Geneva — The World Health Organization (WHO) will begin distributing a paediatric (chewable) formulation of mebendazole to countries with a high prevalence of soil-transmitted helminthiases (intestinal worms). Mebendazole is one of the medicines recommended by WHO to treat intestinal worm infections of humans. This formulation was approved by the United States Food and Drug Administration in 2016 and is now donated to WHO by the pharmaceutical company Johnson & Johnson...

::::::

## Weekly Epidemiological Record, 22 June 2018, vol. 93, 25 (pp. 357–368)

- :: Joint External Evaluation in crisis countries a perspective from the Eastern Mediterranean Region
- :: Strategic response to an outbreak of circulating vaccine-derived poliovirus type 2, Syrian Arab Republic, 2017–2018

::::::

## **WHO Regional Offices**

Selected Press Releases, Announcements

## **WHO African Region AFRO**

Selected Featured News

- :: <u>Polio Eradication-Regional Certification Commission concludes meeting with far-reaching recommendations for countries</u> 22 June 2018
- :: On the hunt for Ebola in the Democratic Republic of Congo 21 June 2018
- :: <u>Maximising digital health technology to improve quality and patient safety in Africa</u> 20 June 2018
- :: Zimbabwe reaches One million men with Voluntary Medical Male Circumcision 19 June 2018
- :: Nigeria and Africa on track to eradicating poliomyelitis says Minister of Health 18 June 2018

#### **WHO Region of the Americas PAHO**

- No new announcements identified.

## **WHO South-East Asia Region SEARO**

- No new announcements identified.

#### **WHO European Region EURO**

- :: Is European Region ready to respond to next influenza pandemic? 21-06-2018
- :: WHO opens new Country Office in Greece 20-06-2018
- :: World Refugee Day: WHO trains Syrian refugees to serve as home-care staff to older and disabled refugees in Turkey 19-06-2018
- :: Commemorating the impact of Semmelweis' work on global health 19-06-2018
- :: Investment and innovation for inclusive health systems key to nations' prosperity 18-06-2018

#### **WHO Eastern Mediterranean Region EMRO**

:: World Refugee Day 2018

19 June 2018 – On World Refugee Day 2018, the WHO Regional Office for the Eastern Mediterranean calls for renewed support for the protection and well-being of refugees and other

displaced populations, and their right to seek health services with dignity, without discrimination, and without undergoing financial hardship...

### **WHO Western Pacific Region**

- No new announcements identified.

::::::

**CDC/ACIP** [to 23 Jun 2018]

http://www.cdc.gov/media/index.html

https://www.cdc.gov/vaccines/acip/index.html

## **MMWR News Synopsis for June 21, 2018**

<u>Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 — Syria, 2017–2018</u>

The 2017 circulating vaccine-derived poliovirus type 2 (cVDPV22) outbreak in Syria underscores the risk of emergence of vaccine-derived polioviruses in settings of low oral poliovirus vaccine (OPV) coverage and also demonstrates the effectiveness of targeted vaccination using monovalent OPV type 2 in controlling cVDPV2 outbreaks. In areas with very low oral poliovirus vaccine (OPV) coverage, prolonged transmission of vaccine-associated viruses can lead to the emergence of vaccine-derived polioviruses (VDPVs). In 2017, an outbreak of circulating VDPV type 2 (cVDPV2) occurred in Syria, resulting in 74 cases. Implementation of three rounds of monovalent OPV type 2 campaigns coupled with intensified surveillance interrupted the outbreak. A longstanding humanitarian crisis, precipitated by war and political unrest, has left much of Syria's population vulnerable to recurrent disease outbreaks, including the recent cVDPV2 outbreak. Subnational gaps in acute flaccid paralysis (AFP) surveillance performance and delays in receiving laboratory results, due to difficulties transporting stool specimens, as a result of the country's complex humanitarian emergency, contributed to the inability to detect the outbreak earlier.

::::::

**Africa CDC** [to 23 Jun 2018] https://au.int/en/africacdc
No new digest content identified.

::::::

#### **China CDC**

http://www.chinacdc.cn/en/ne/ Website not responding at inquiry...no connection since 2 June inquiry

::::::

**ECDC - European Centre for Disease Prevention and Control** [to 23 Jun 2018]

https://ecdc.europa.eu/en/home

Publication

## ECDC public health microbiology strategy 2018–2022

corporate publication - 20 Jun 2018

Data

## <u>HEPSA – health emergency preparedness self-assessment tool</u>

tool - 20 Jun 2018

News

## **ECDC launches preparedness self-assessment tool**

- 20 Jun 2018

ECDC launches the HEPSA (Health Emergency Preparedness Self-Assessment) tool, in order to support countries in improving their level of public health emergency preparedness.

::::::

## **Announcements**

**AERAS** [to 23 Jun 2018]

http://www.aeras.org/pressreleases
No new digest content identified.

## **BMGF - Gates Foundation** [to 23 Jun 2018]

http://www.gatesfoundation.org/Media-Center/Press-Releases No new digest content identified.

## **Bill & Melinda Gates Medical Research Institute** [to 23 Jun 2018]

https://www.linkedin.com/company/bill-melinda-gates-medical-research-institute/

The Bill & Melinda Gates Medical Research Institute is a non-profit research organization dedicated to combating diseases that impact the world's poorest. We strive to combat inequities in health by accelerating progress in translational science to ensure life-saving products are available and accessible to everyone. We consider ourselves pioneers dedicated to uncovering radical solutions that will close the gap between cutting-edge scientific innovation and its application to challenges in global health.

No new digest content identified...

#### **CARB-X** [to 23 Jun 2018]

https://carb-x.org/

CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. No new digest content identified.

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 23 Jun 2018]

http://cepi.net/

No new digest content identified.

## **EDCTP** [to 23 Jun 2018]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials No new digest content identified.

### **Emory Vaccine Center** [to 23 Jun 2018]

http://www.vaccines.emory.edu/ No new digest content identified.

## **European Medicines Agency** [to 23 Jun 2018]

http://www.ema.europa.eu/ema/

22/06/2018

## Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19–21 June 2018

First stem cell-based veterinary medicine recommended for marketing authorisation ...

22/06/2018

#### Reinforced EU/US collaboration on medicines

Update on the European Commission/EMA-FDA bilateral of 18-19 June 2018 ...

21/06/2018

## <u>Interested in joining the Committee for Advanced Therapies (CAT) to represent patients' associations or clinicians?</u>

Call for expressions of interest open until 18 July 2018 ...

19/06/2018

### Modernising the orphan designation process

EMA launches new submission portal today

## **European Vaccine Initiative** [to 23 Jun 2018]

http://www.euvaccine.eu/news-events No new digest content identified.

#### **FDA** [to 23 Jun 2018]

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm No new digest content identified.

### Fondation Merieux [to 23 Jun 2018]

http://www.fondation-merieux.org/ No new digest content identified.

**Gavi** [to 23 Jun 2018]

http://www.gavi.org/library/news/press-releases/

No new digest content identified.

## **GHIT Fund** [to 23 Jun 2018]

https://www.ghitfund.org/newsroom/press

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world's poorest people. Other funders include six Japanese pharmaceutical No new digest content identified.

## **Global Fund** [to 23 Jun 2018]

http://www.theglobalfund.org/en/news/?topic=&type=NEWS;&country=

Global Fund Appoints New Head of External Relations, Chief Financial Officer and Chief Information Officer

20 June 2018

Peter Sands, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, today announced the appointments of three new leaders joining the senior management team to accelerate the Global Fund's work toward ending epidemics.

Françoise Vanni will become the Global Fund's new Head of External Relations, bringing more than 20 years of leadership experience in resource mobilization and advocacy, most recently as Director of External Relations and Communications for the United Nations Relief and Works Agency in the Middle East.

Jacques Le Pape, a finance expert with rich experience in government and in the private sector, will be the Global Fund's new Chief Financial Officer. Le Pape has served as a senior auditor, an executive at Air France KLM, an advisor to successive ministers in the French government, and as a manager at France's Treasury. He will begin his new role on 23 July.

Michael Johnson, an innovative and accomplished leader in information technology with experience in both the public and private sectors, will become the new Chief Information Officer at a time when the Global Fund is building greater capacity for managing and synthesizing data with a focus on an enhanced digital agenda...

## **Hilleman Laboratories** [to 23 Jun 2018]

http://www.hillemanlabs.org/ No new digest content identified.

**Human Vaccines Project** [to 23 Jun 2018]

http://www.humanvaccinesproject.org/media/press-releases/

Media Release: 19-Jun-2018

## <u>Michelson Prize Awards \$450,000 to Young Scientists Advancing Immunology and Vaccine Research</u>

The Michelson Medical Research Foundation and the Human Vaccines Project award three recipients with inaugural Michelson Prizes for Human Immunology and Vaccine Research

...Today the <u>Michelson Medical Research Foundation</u> and the <u>Human Vaccines Project</u> are announcing the cutting edge researchers under the age of 35 that were selected as the award's first recipients from a global competition that included over a hundred applications spanning 12 countries. Each of the three recipients will be awarded a \$150,000 Prize to fund specific aspects of their research.

"We are thrilled to recognize these three young scientists that hail from the U.S. and Australia – Patricia Illing, PhD, Ansuman Satpathy, MD, PhD, and Laura Mackay, PhD – as the first recipients of the Michelson Prizes for Human Immunology and Vaccine Research," said Gary Michelson, MD, founder of the Michelson Medical Research Foundation. "The high caliber of their scientific pursuits, their disruptive ideas, and their passion for innovation and problem solving gives me great hope for the future of science."...

**IAVI** [to 23 Jun 2018] <a href="https://www.iavi.org/">https://www.iavi.org/</a> *No new digest content identified.* 

#### **IFFIm**

http://www.iffim.org/library/news/press-releases/ No new digest content identified.

**IVAC** [to 23 Jun 2018]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html June 2018

<u>Commentary: The Ideal Community of Practice—Engaging Local Stakeholders in</u>
Uganda to Develop Cost of Illness Estimates and Beyond

IVI [to 23 Jun 2018] http://www.ivi.int/ [Undated]

NIBSC, IVI jointly organize meeting on cholera vaccine standardization

[Undated]

## In Memoriam: Prof. Adel Mahmoud (1941 - 2018)

The International Vaccine Institute (IVI) is greatly saddened by the June 11 passing of Prof. Adel Mahmoud, former Chairman of the IVI Board of Trustees and a global pioneer in the treatment and prevention of infectious diseases.

Prof. Mahmoud joined the IVI BOT as a member-at-large in 2010 and served as its Chairman from 2013 when IVI was going through a difficult period, before resigning due to health reasons in February of this year. He came to the IVI Board after a remarkable career in academia and industry, culminating as the President of Merck Vaccines. Before passing away,

he was a Professor of the Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs at Princeton University, USA.

IVI is a stronger and more vital institution because of Prof. Mahmoud's vision and leadership. IVI is eternally grateful to him and would like to extend our deepest and most sincere condolences to his family and to all those who knew him, as we join the community in the mourning of his loss. He will be remembered and dearly missed by IVI and the broader international community for his contributions to global health.

**JEE Alliance** [to 23 Jun 2018] <a href="https://www.jeealliance.org/">https://www.jeealliance.org/</a> *No new digest content identified.* 

MSF/Médecins Sans Frontières [to 23 Jun 2018]

http://www.msf.org/en/updates
No new digest content identified.

NIH [to 23 Jun 2018] http://www.nih.gov/news-events/news-releases No new digest content identified.

**PATH** [to 23 Jun 2018]

http://www.path.org/news/index.php

Press release | June 20, 2018

<u>PATH and SD BIOSENSOR announce partnership to advance diagnostic test critical</u> for malaria treatment and elimination

Agreement supports development and availability of an affordable, high-quality enzyme deficiency test

Press release | June 19, 2018

New report finds \$100 million shortfall in annual global investments in malaria research and development

Report highlights a 'second valley of death' threatening to keep developed malaria products from reaching those most in need

[See Research/Reports below for more detail]

Sabin Vaccine Institute [to 23 Jun 2018]

http://www.sabin.org/updates/pressreleases

No new digest content identified.

**UNAIDS** [to 23 Jun 2018] http://www.unaids.org/en Update

## Women's rights advocates join UNAIDS to address sexual harassment

22 June 2018

For decades, women's rights leaders and civil society organizations have been actively working to advance gender equality. Civil society have also been critical partners to UNAIDS since its inception in 1996, UNAIDS being the only United Nations organization to include non-governmental organizations as active participants on its board.

The partnership between UNAIDS and civil society continues to be essential and on 18-19 June, UNAIDS and the ATHENA Network co-convened a meeting on addressing sexual harassment. The meeting provided a unique opportunity for dialogue with civil society on concerns and questions around sexual harassment and gender equality, as well as to provide valuable inputs on how to strengthen the work of UNAIDS in this area.

UNAIDS welcomed more than 30 women's rights leaders and civil society advocates to share good practices, articulate concerns and discuss ways of moving forward to strengthen rights-based responses to sexual harassment and protect survivors and people who come forward to report incidents of harassment...

**UNICEF** [to 23 Jun 2018]

https://www.unicef.org/media/ Selected Press Releases/Reports

No new digest content identified...most recent press release dated 15 May 2018]

Vaccine Confidence Project [to 23 Jun 2018]

http://www.vaccineconfidence.org/ No new digest content identified.

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 23 Jun 2018]

http://www.chop.edu/centers-programs/vaccine-education-center No new digest content identified.

Wellcome Trust [to 23 Jun 2018]

https://wellcome.ac.uk/news No new digest content identified.

The Wistar Institute [to 23 Jun 2018]

https://www.wistar.org/news/press-releases No new digest content identified.

**World Organisation for Animal Health (OIE)** [to 23 Jun 2018]

http://www.oie.int/en/for-the-media/press-releases/2018/

20/06/18

**Discover the 2017 OIE Annual Report** 

To meet the goal of protecting animals and thereby preserving our future, the World Organisation for Animal Health (OIE) worked in 2017 with its 181 Member Countries to control animal health risks, ensure transparency in communication and reinforce the resilience of animal health systems: the 3 main objectives of its 6th Strategic Plan. This Annual Report reviews the progress achieved over the past year.

::::::

**BIO** [to 23 Jun 2018]

https://www.bio.org/insights/press-release

Jun 21 2018

## <u>Distinguished Professor and Dean from South Korea to Receive 2018 George</u> Washington Carver Award

The Biotechnology Innovation Organization (BIO) today announced that Distinguished Professor Sang Yup Lee at the Department of Chemical and Biomolecular Engineering at the Korea Advanced Institute of Science and Technology (KAIST) will receive the 11th annual George Washington Carver Award for Innovation in Industrial Biotechnology. The award will be presented on Wednesday, July 18, 2018 during a plenary session at the 2018 BIO World Congress on Industrial Biotechnology. The world's largest conference on industrial biotechnology and partnering event will be held July 16-19, 2018, at the Pennsylvania Convention Center in Philadelphia.

Jun 21 2018

## Corteva Agriscience's Krysta Harden to Receive 2018 Rosalind Franklin Award

The Biotechnology Innovation Organization (BIO) today announced that Corteva AgriscienceTM Vice President of External Affairs and Chief Sustainability Officer Krysta Harden will receive the 5th annual Rosalind Franklin Award for Leadership in Industrial Biotechnology and Agriculture. Corteva Agriscience™ is the Agriculture Division of DowDuPont. The award will be presented on Wednesday, July 18, 2018 during a plenary session at the 2018 BIO World Congress on Industrial Biotechnology. The world's largest conference on industrial biotechnology and partnering event will be held July 16-19, 2018, at the Pennsylvania Convention Center in Philadelphia.

#### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 23 Jun 2018]

http://www.dcvmn.org/

No new digest content identified.

**IFPMA** [to 23 Jun 2018]

http://www.ifpma.org/resources/news-releases/

No new digest content identified.

**PhRMA** [to 23 Jun 2018]

http://www.phrma.org/press-room

No new digest content identified.

\* \* \* \* \*

## <u>Reports/Research/Analysis/Commentary/Conferences/Meetings/Book</u> <u>Watch/Tenders</u>

*Vaccines and Global Health: The Week in Review* has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

## Bridging the gaps in malaria R&D: An analysis of funding—from basic research and product development to research for implementation

June 2018:: 20 pages PDF: <a href="http://www.path.org/news/press-room/881/">http://www.path.org/news/press-room/881/</a>

The development of this <u>report</u> was undertaken by <u>PATH</u>, the <u>Special Programme for Research and Training in Tropical Diseases</u>, and <u>Malaria No More UK</u>, in collaboration with the <u>Foundation for Innovative New Diagnostics</u>, <u>Innovative Vector Control Consortium</u>, <u>Medicines for Malaria Venture</u>, and the <u>World Health Organization's Global Malaria Programme</u>. Data collection was completed by Policy Cures Research.

Support for the development and dissemination of the report was provided by the Bill & Melinda Gates Foundation and the ExxonMobil Foundation. The views expressed in the report or related materials are solely those of the authors and do not necessarily reflect the views of the funders.

#### Press Release

## New report finds \$100 million shortfall in annual global investments in malaria research and development

Report highlights a 'second valley of death' threatening to keep developed malaria products from reaching those most in need

London and Washington, DC, 19 June 2018—A <u>new report</u> on the state of funding of malaria research and development (R&D) globally shows that funding for basic research and product development falls short of the need.

"Right now, annual investments in basic research and product development for malaria are about US \$100 million less than what is required to meet funding targets," said David C. Kaslow, MD, Vice President of Essential Medicines at PATH. "We see evidence of this shortfall across malaria R&D. In addition to that gap, however, we now face a 'second valley of death'—not enough resources to move products through development, all the way to impact."

The report, Bridging the gaps in malaria R&D: An analysis of funding—from basic research and product development to research for implementation, combines original research with regularly reported data on funding for basic research and product development. It is the first time a report has quantified the funds not only devoted to initial product development but to the additional research to improve access to those prevention or treatment products. This research for implementation included implementation research, operational research, and health systems research.

The report spotlights the results of a pilot survey of leading funders of malaria R&D covering a three-year period, 2014–2016. It found that research for implementation comprised 16% of total average annual malaria R&D investments of \$673 million, averaging \$107 million annually...

The report makes three overarching recommendations on basic research and product development in malaria, and five additional recommendations specific to research for implementation.

## Overarching recommendations from the report:

- 1. Improve coordination across intervention areas (from basic through implementation research). Product developers must work together to ensure that next-generation interventions will fit together seamlessly.
- 2. Develop more innovative funding approaches. New types and approaches of funding mechanisms and incentives are clearly needed.
- 3. Continue existing tracking of funding flows and strengthen systems to address data gaps. Key stakeholders, including those who have experience tracking resource flows and conducting research, should work together—in particular, on research for implementation.

## Key research for implementation topics recommended for discussion:

- A. Agree to definitions and a core data set to track research for implementation. The use of a range of definitions complicates and, in some cases, prevents tracking and analysis into funding flows. Few funders are doing this, and many who would like to do this do not have the systems or personnel to do it.
- B. Determine how to collect data on research for implementation funding at the institutional, national, and subnational levels. This survey has been limited to a subset of organizations. However, there is a deep well of research to be mined at the local level that is necessary to complete the full picture.
- C. Investigate the value of tracking funding for training and capacity building for research for implementation. Several organizations provided funding for building this capacity, yet this report (and others) have identified gaps in research capacity. Can the tracking of funding for training be useful for funders and program planners?
- D. Review diagonal versus horizontal research for implementation. How can the outcomes of research for implementation be shared across health systems so that the learnings do not remain siloed within a particular disease area or type of intervention?
- E. Consider a funding target for research for implementation as part of any elimination or control program. The goal would be to increase funding to the areas with the greatest gaps, not to reallocate from within the current funding pool.

\* \* \* \*

### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant

to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

#### **American Journal of Infection Control**

June 2018 Volume 46, Issue 6, p601-732, e31-e42 <a href="http://www.ajicjournal.org/current">http://www.ajicjournal.org/current</a> [Reviewed earlier]

#### **American Journal of Preventive Medicine**

June 2018 Volume 54, Issue 6, p727-848 <a href="http://www.ajpmonline.org/current">http://www.ajpmonline.org/current</a> [Reviewed earlier]

#### **American Journal of Public Health**

June 2018 108(6) <a href="http://ajph.aphapublications.org/toc/ajph/current">http://ajph.aphapublications.org/toc/ajph/current</a> [Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 98, Issue 6, 2018 http://www.ajtmh.org/content/journals/14761645/98/6 [Reviewed earlier]

### **Annals of Internal Medicine**

19 June 2018 Vol: 168, Issue 12 <a href="http://annals.org/aim/issue">http://annals.org/aim/issue</a>
Position Papers | 19 June 2018

## <u>Women's Health Policy in the United States: An American College of Physicians</u> Position Paper

Hilary Daniel, BS; Shari M. Erickson, MPH; Sue S. Bornstein, MD; for the Health and Public Policy Committee of the American College of Physicians \*

Abstract

In this position paper, the American College of Physicians (ACP) examines the challenges women face in the U.S. health care system across their lifespans, including access to care; sex-and gender-specific health issues; variation in health outcomes compared with men; underrepresentation in research studies; and public policies that affect women, their families, and society. ACP puts forward several recommendations focused on policies that will improve the health outcomes of women and ensure a health care system that supports the needs of women and their families over the course of their lifespans.

## **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 23 Jun 2018) [No new digest content identified]

#### **BMJ Global Health**

May 2018 - Volume 3 - 3 http://gh.bmj.com/content/3/3 [Reviewed earlier]

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 23 Jun 2018) [No new digest content identified]

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 23 Jun 2018) [No new digest content identified]

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 23 Jun 2018) [No new digest content identified]

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 23 Jun 2018) Research article

## Simple rules for evidence translation in complex systems: A qualitative study

Ensuring patients benefit from the latest medical and technical advances remains a major challenge, with rational-linear and reductionist approaches to translating evidence into practice proving inefficient and ineffective. Complexity thinking, which emphasises interconnectedness and unpredictability, offers insights to inform evidence translation theories and strategies. Drawing on detailed insights into complex micro-systems, this research aimed to advance empirical and theoretical understanding of the reality of making and sustaining improvements in complex healthcare systems.

Authors: Julie E. Reed, Cathy Howe, Cathal Doyle and Derek Bell

Citation: BMC Medicine 2018 16:92

Published on: 20 June 2018

#### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content

(Accessed 23 Jun 2018)

[No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 23 Jun 2018) [No new digest content identified]

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content

(Accessed 23 Jun 2018)

Research note

## <u>Brief report: Parental attitudes and knowledge on routine childhood immunization:</u> an experience from Central Sri Lanka

A lack of correct awareness about immunization among parents put them at risk of falling prey to the anti-vaccine movement. This risk is present even in countries with a high vaccine uptake. This study was don...

Authors: N. C. Herath, T. Kudagammana, T. T. Sanathchandra, H. K. Gamage, I. M. Razik and

V. Liynapathirana

Citation: BMC Research Notes 2018 11:402

Published on: 22 June 2018

#### **BMJ Open**

June 2018 - Volume 8 - 6 http://bmjopen.bmj.com/content/current [Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 96, Number 6, June 2018, 369-440 <a href="http://www.who.int/bulletin/volumes/96/6/en/">http://www.who.int/bulletin/volumes/96/6/en/</a> [Reviewed earlier]

#### **Child Care, Health and Development**

Volume 44, Issue 4 Pages: 507-658 July 2018 https://onlinelibrary.wiley.com/toc/13652214/current ORIGINAL ARTICLES

## Factors associated with delayed infant immunization in a nationally representative cohort study

[Australia - Parental attitudes accounted for a relatively small percentage of delayed infant immunization. In contrast, many children who did not receive vaccines on time were characterized by social disadvantage, especially larger family size. Researchers and policy-makers should consider how to make timely immunization easier for busy parents.

J. Homel, B. Edwards

Pages: 583-591

First Published: 20 February 2018

## **Clinical and Experimental Vaccine Research**

Volume 7(1); January 2018 http://ecevr.org/ [Reviewed earlier]

## **Clinical Therapeutics**

June 2018 Volume 40, Issue 6, p813-1048 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

#### **Clinical Trials**

Volume: 15, Number: 3 (June 2018) http://journals.sagepub.com/toc/ctja/15/3 [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 23 Jun 2018] [No new digest content identified]

#### **Contemporary Clinical Trials**

Volume 70 Pages 1-138 (July 2018) <a href="https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/70/suppl/C">https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/70/suppl/C</a> [Reviewed earlier]

#### **Current Opinion in Infectious Diseases**

June 2018 - Volume 31 - Issue 3 <a href="http://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx">http://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Developing World Bioethics**

Volume 18, Issue 2 Pages: 65-203 June 2018 <a href="https://onlinelibrary.wiley.com/toc/14718847/current">https://onlinelibrary.wiley.com/toc/14718847/current</a> [Reviewed earlier]

## **Development in Practice**

Volume 28, Issue 5, 2018
<a href="http://www.tandfonline.com/toc/cdip20/current">http://www.tandfonline.com/toc/cdip20/current</a>
[New issue; No digest content identified]

### **Disaster Medicine and Public Health Preparedness**

Volume 12 - Issue 2 - April 2018 https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue [Reviewed earlier]

#### **Disasters**

Volume 42, Issue 3 Pages: 405-612 July 2018 <a href="https://onlinelibrary.wiley.com/toc/14677717/current">https://onlinelibrary.wiley.com/toc/14677717/current</a> [Reviewed earlier]

## **EMBO Reports**

01 June 2018; volume 19, issue 6 http://embor.embopress.org/content/19/6?current-issue=y Opinion

## **Nobody at the top**

Science bears some hallmarks of religion. But, unlike many organized religions, there is no central authority and no tenet remains unchallenged.

EMBO Reports (2018) 19: e46329 Brooke Morriswood, Oliver Hoeller

#### Opinion

### Reproducibility crisis in science or unrealistic expectations?

The reproducibility crisis in biomedical research has spurred much debate about the causes of the failure to validate experimental results. But the discussion may be overlooking one crucial factor that is inherent to research with low sample sizes: random variation.

EMBO Reports (2018) 19: e46008

Thiago FA França, José Maria Monserrat

## **Emerging Infectious Diseases**

Volume 24, Number 6—June 2018 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

#### **Epidemics**

Volume 23 Pages 1-120 (June 2018) <a href="https://www.sciencedirect.com/journal/epidemics/vol/22/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/22/suppl/C</a> [Reviewed earlier]

## **Epidemiology and Infection**

Volume 146 - Issue 8 - June 2018 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

## The European Journal of Public Health

Volume 28, Issue 3, 1 June 2018 <a href="https://academic.oup.com/eurpub/issue/28/3">https://academic.oup.com/eurpub/issue/28/3</a> [Reviewed earlier]

#### **Global Health Action**

Volume 11, 2018 – Issue 1 <a href="https://www.tandfonline.com/toc/zgha20/11/1?nav=tocList">https://www.tandfonline.com/toc/zgha20/11/1?nav=tocList</a> [Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 6, No. 1 March 21, 2018 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

#### **Global Public Health**

Volume 13, 2017 Issue 8
<a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a>

Special Symposium: Critical Perspectives on the 'End of AIDS'.

Guest Editors: Nora Kenworthy, Matthew Thomann, and Richard Parker [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 23 Jun 2018] Research 20 June 2018

#### Does quality influence utilization of primary health care? Evidence from Haiti

Expanding coverage of primary healthcare services such as antenatal care and vaccinations is a global health priority; however, many Haitians do not utilize these services. One reason may be that the population avoids low quality health facilities. We examined how facility infrastructure and the quality of primary health care service delivery were associated with community utilization of primary health care services in Haiti.

Authors: Anna D. Gage, Hannah H. Leslie, Asaf Bitton, J. Gregory Jerome, Jean Paul Joseph, Roody Thermidor and Margaret E. Kruk

### **Health Affairs**

June 2018 Vol. 37 , No. 6 https://www.healthaffairs.org/toc/hlthaff/current *Hospitals, Primary Care & More* [Reviewed earlier]

## **Health and Human Rights**

Volume 20, Issue 1, June 2018 <a href="http://www.hhrjournal.org/">http://www.hhrjournal.org/</a>

## Special Section on Neglected Tropical Diseases and Human Rights

in collaboration with Helen Keller International, USA and with financial support from Children's Investment Fund Foundation, London, UK

<u>FOREWORD Embodying Law and Embedding Public Health with the Voices of Those</u>
Affected: Ending NTDs by 2030

Alice Cruz

## EDITORIAL "Equipping Practitioners": Linking Neglected Tropical Diseases and Human Rights

Joseph J. Amon and David G. Addiss

In 2007, Paul Hunt, the United Nations Special Rapporteur on the right to health, and colleagues published a report entitled Neglected Diseases: A Human Rights Analysis. In introducing the report, the authors wrote:

The human rights implications of neglected diseases, and the contribution that human rights can make to addressing neglected diseases, have not been given the attention they deserve. This report aims to equip practitioners with an understanding of human rights, how human rights abuses cause and result from neglected diseases, and how a human rights approach can contribute to the fight against neglected diseases.[1]

More than a decade later, the human rights implications of neglected tropical diseases (NTDs) are still only infrequently addressed, and there remains a need to "equip practitioners"—in both the NTD and the human rights fields—and to ensure that rights-based principles and approaches are examined and integrated into NTD programs. Seeking to expand this attention, the call for articles for this special issue of Health and Human Rights Journal asked NTD scholars and practitioners to share examples of how rights interact with NTDs and how current NTD programs respect, protect, and promote human rights...

**Special Section on Judicial Enforcement of Health Rights: Focus on Latin America** in collaboration with the O'Neill Institute, Georgetown University, Washington DC, USA June 20, 2018

## **EDITORIAL Health in the Courts of Latin America**

Octávio Luiz Motta Ferraz

To address any complex issue in a large and diverse geographical region of the world is always a daunting and risky task. Latin America is no exception. Despite the semblance of uniformity that the use of the term "Latin American" often misleadingly imparts, the truth is that there is no such thing as a homogeneous bloc of countries occupying the territory running from the border between the United States and Mexico down to Uruguay, plus a few islands in the Caribbean Sea. Not even a single language is shared, let alone a broader "Latin American culture."

We are dealing with a large region spanning 20 million square kilometers (13% of the earth's land surface), including very poor countries such as Haiti, middle-income ones such as Peru, Colombia, and Brazil, and relatively wealthy ones such as Uruguay and Argentina. There are democracies at different levels of maturity and stability alongside authoritarian regimes, as well as a diverse range of political-economic systems, from socialist Cuba to economically liberal Chile. [1] Health systems also vary significantly in their structures (from national health services in Brazil to social security and public insurance schemes in Mexico and Colombia), coverage, and quality. As an influential historian has recently claimed, the idea of Latin America should have probably vanished by now. But he also acknowledges that "[t]he term is here to stay, and it is important."[2]

The topic addressed in this special section—the judicial enforcement of health rights—inevitably reflects this remarkable diversity. Despite some interesting common trends, no "Latin American model" of health litigation emerges, unsurprisingly, from the growing but still limited studies of the past few decades (including those published in this issue). On the contrary, there is significant variety in terms of the magnitude of the phenomenon, its main characteristics, its potential causes, the impact it has on equity and health systems, and the emerging initiatives in reaction to the phenomenon...

#### General Papers

## <u>Access to Medicines in Times of Conflict: Overlapping Compliance and Accountability</u> Frameworks for Syria

Brianne McGonigle Leyh and Marie Elske Gispen *Abstract* 

Syria is currently experiencing the world's largest humanitarian crisis since World War II, and access to medicines for emergency care, pain control, and palliative care remains shockingly restricted in the country. Addressing the dire need for improved access to medicines in Syria from an international law compliance and accountability perspective, this article highlights four complementary legal frameworks: international human rights law, international drug control law, international humanitarian law, and international criminal law. It arrives at two central conclusions. First, all four bodies of law hold clear potential in terms of regulatory—hence compliance—and accountability mechanisms for improving access to medicines in times of conflict, but they are too weak on their own account. Second, the potential for on-the-ground change lies in the mutual reinforcement of these four legal frameworks. This reinforcement, however, remains rhetorical and far from practical. Finally, within this complex picture of complementary international legal frameworks, the article proposes concrete recommendations for a more integrated and mutually reinforcing interpretation and implementation of these areas of law to foster better access to medicines in Syria and elsewhere.

## Missing: Where Are the Migrants in Pandemic Influenza Preparedness Plans?

Kolitha Wickramage, Lawrence O. Gostin, Eric Friedman, Phusit Prakongsai, Rapeepong Suphanchaimat, Charles Hui, Patrick Duigan, Eliana Barragan, and David Harper

#### **Health Economics, Policy and Law**

Volume 13 - Special Issue 3-4 - July 2018

https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue SPECIAL ISSUE: Canadian Medicare: Historical Reflections, Future Directions

[New issue; No digest content identified]

## **Health Equity**

Volume 2 Issue 1 Jun 2018 https://www.liebertpub.com/toc/heg/2/1 [Reviewed earlier]

### **Health Policy and Planning**

Volume 33, Issue 6, 1 July 2018 http://heapol.oxfordjournals.org/content/current [New issue; No digest content identified]

## **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 23 Jun 2018] Research

## Priority-setting in public health research funding organisations: an exploratory qualitative study among five high-profile funders

Priority-driven funding streams for population and public health are an important part of the health research landscape and contribute to orienting future scholarship in the field. While research priorities are often made public through targeted calls for research, less is known about how research funding organisations arrive at said priorities. Our objective was to explore how public health research funding organisations develop priorities for strategic extramural research funding programmes.

Authors: Yuri Cartier, Maria I. Creatore, Steven J. Hoffman and Louise Potvin

Citation: Health Research Policy and Systems 2018 16:53

Published on: 22 June 2018

#### **Humanitarian Exchange Magazine**

Number 71 March 2018

https://odihpn.org/magazine/humanitarian-response-urban-areas/

#### **Humanitarian response in urban areas**

Humanitarian crises are increasingly affecting urban areas either directly, through civil conflict, hazards such as flooding or earthquakes, urban violence or outbreaks of disease, or indirectly, through hosting people fleeing these threats. The humanitarian sector has been slow to understand how the challenges and opportunities of working in urban spaces necessitate changes in how they operate. For agencies used to working in rural contexts, the dynamism of the city, with its reliance on markets, complex systems and intricate logistics, can be a daunting challenge. Huge, diverse and mobile populations complicate needs assessments, and close coordination with other, often unfamiliar, actors is necessary.

[Reviewed earlier]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 14, Issue 5 2018

## http://www.tandfonline.com/toc/khvi20/current

[Reviewed earlier]

## **Infectious Agents and Cancer**

http://www.infectagentscancer.com/content [Accessed 23 Jun 2018] [No new digest content identified]

## **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 23 Jun 2018] [No new digest content identified]

#### **International Health**

Volume 10, Issue 3, 1 May 2018 <a href="http://inthealth.oxfordjournals.org/content/current">http://inthealth.oxfordjournals.org/content/current</a> [Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol 5, No 6 (2018) June 2018 http://www.ijcmph.com/index.php/ijcmph/issue/view/39 [Reviewed earlier]

## **International Journal of Epidemiology**

Volume 47, Issue 2, 1 April 2018, Pages 359 <a href="https://academic.oup.com/ije/issue/47/2">https://academic.oup.com/ije/issue/47/2</a> [Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 11 Issue 2 2018 <a href="https://www.emeraldinsight.com/toc/ijhrh/11/2">https://www.emeraldinsight.com/toc/ijhrh/11/2</a> [Reviewed earlier]

#### **International Journal of Infectious Diseases**

June 2018 Volume 71, p1-124 <a href="https://www.ijidonline.com/issue/S1201-9712(18)X0005-8">https://www.ijidonline.com/issue/S1201-9712(18)X0005-8</a> [Reviewed earlier]

### **JAMA**

June 19, 2018, Vol 319, No. 23, Pages 2349-2450

http://jama.jamanetwork.com/issue.aspx
Viewpoint

## An Incomplete Prescription - President Trump's Plan to Address High Drug Prices

Ameet Sarpatwari, JD, PhD; Jerry Avorn, MD; Aaron S. Kesselheim, MD, JD, MPH JAMA. 2018;319(23):2373-2374. doi:10.1001/jama.2018.7424

This Viewpoint discusses missed opportunities in the 2018 White House blueprint to reduce prescription drug prices, including a proposal that would require CMS to negotiate prices with manufacturers and that would ban unfair practices companies use to extend brand exclusivity.

#### **JAMA Pediatrics**

June 2018, Vol 172, No. 6, Pages 505-604 http://archpedi.jamanetwork.com/issue.aspx [Reviewed earlier]

## **JBI Database of Systematic Review and Implementation Reports**

June 2018 - Volume 16 - Issue 6 http://journals.lww.com/jbisrir/Pages/currenttoc.aspx [New issue; No digest content identified]

#### **Journal of Adolescent Health**

June 2018 Volume 62, Issue 6, p633-754 <a href="https://www.jahonline.org/issue/S1054-139X(17)X0021-9">https://www.jahonline.org/issue/S1054-139X(17)X0021-9</a> [Reviewed earlier]

## **Journal of Community Health**

Volume 43, Issue 3, June 2018 <a href="https://link.springer.com/journal/10900/43/3/page/1">https://link.springer.com/journal/10900/43/3/page/1</a> [Reviewed earlier]

## **Journal of Empirical Research on Human Research Ethics**

Volume 13, Issue 3, July 2018 <a href="http://journals.sagepub.com/toc/jre/current">http://journals.sagepub.com/toc/jre/current</a> [Reviewed earlier]

## **Journal of Epidemiology & Community Health**

June 2018 - Volume 72 - 6
<a href="http://jech.bmj.com/content/current">http://jech.bmj.com/content/current</a>
[New issue; No digest content identified]

#### **Journal of Evidence-Based Medicine**

Volume 11, Issue 2 Pages: 69-129 May 2018

## https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 13, Issue 3, 2017 <a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a> [Reviewed earlier]

## **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 29, Number 2, May 2018 <a href="https://muse.jhu.edu/issue/38537">https://muse.jhu.edu/issue/38537</a> [Reviewed earlier]

## **Journal of Humanitarian Logistics and Supply Chain Management**

Volume 8 Issue 1 2018 <a href="https://www.emeraldinsight.com/toc/jhlscm/8/1">https://www.emeraldinsight.com/toc/jhlscm/8/1</a> [Reviewed earlier]

## **Journal of Immigrant and Minority Health**

Volume 20, Issue 3, June 2018 <a href="https://link.springer.com/journal/10903/20/3/page/1">https://link.springer.com/journal/10903/20/3/page/1</a> [Reviewed earlier]

## **Journal of Immigrant & Refugee Studies**

Volume 16, 2018\_ Issue 3 <a href="http://www.tandfonline.com/toc/wimm20/current">http://www.tandfonline.com/toc/wimm20/current</a> [Reviewed earlier]

#### **Journal of Infectious Diseases**

Volume 217, Issue 11, 23 Jun 2018 <a href="https://academic.oup.com/jid/issue/217/1">https://academic.oup.com/jid/issue/217/1</a> [Reviewed earlier]

## **Journal of Medical Ethics**

June 2018 - Volume 44 - 6 http://jme.bmj.com/content/current [Reviewed earlier]

#### **Journal of Medical Internet Research**

Vol 20, No 6 (2018): June

## http://www.jmir.org/2018/6 [Reviewed earlier]

## **Journal of Medical Microbiology**

Volume 67, Issue 6, June 2018 <a href="http://jmm.microbiologyresearch.org/content/journal/jmm/67/6">http://jmm.microbiologyresearch.org/content/journal/jmm/67/6</a> [Reviewed earlier]

#### **Journal of Patient-Centered Research and Reviews**

Volume 5, Issue 2 (2018) https://digitalrepository.aurorahealthcare.org/jpcrr/ [Reviewed earlier]

## **Journal of the Pediatric Infectious Diseases Society (JPIDS)**

Volume 7, Issue 2 June 2018 <a href="https://academic.oup.com/jpids/issue">https://academic.oup.com/jpids/issue</a> [Reviewed earlier]

#### **Journal of Pediatrics**

June 2018 Volume 197, p1-324 http://www.jpeds.com/current [New issue; No digest content identified]

## **Journal of Pharmaceutical Policy and Practice**

https://joppp.biomedcentral.com/ [Accessed 23 Jun 2018] Research 21 June 2018

Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities

The regulatory requirements for approval of generic medicines and the format of compiling drug dossiers vary among regulatory authorities. The variation is particularly wide between High-income countries (HIC) and lower and middle-income countries (LMIC) with different regulatory frameworks. In this study, document requirements for approval of generic products, approval timelines, and consideration of bioequivalence and/or biowaiver data by Regulatory Authorities (RAs) of 10 selected jurisdictions was studied.

Authors: D. Thambavita, P. Galappatthy and R. L. Jayakody

## **Journal of Public Health Management & Practice**

May/June 2018 - Volume 24 - Issue 3 <a href="https://journals.lww.com/jphmp/pages/currenttoc.aspx">https://journals.lww.com/jphmp/pages/currenttoc.aspx</a>

## [Reviewed earlier]

## **Journal of Public Health Policy**

Volume 39, Issue 2, May 2018 <a href="https://link.springer.com/journal/41271/39/2/page/1">https://link.springer.com/journal/41271/39/2/page/1</a> [Reviewed earlier]

## Journal of the Royal Society - Interface

May 2018; volume 15, issue 142 http://rsif.royalsocietypublishing.org/content/current [Reviewed earlier]

#### **Journal of Travel Medicine**

Volume 25, Issue suppl\_1, 1 May 2018 https://academic.oup.com/jtm/issue/25/suppl\_1 **Asian travel: from the rare to the difficult** [Reviewed earlier]

## **Journal of Virology**

June 2018, volume 92, issue 12 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

## **The Lancet**

Jun 23, 2018 Volume 391 Number 10139 p2475-2574 e24 <a href="https://www.thelancet.com/journals/lancet/issue/current">https://www.thelancet.com/journals/lancet/issue/current</a> [New issue; No digest content identified]

#### **Lancet Global Health**

Jun 2018 Volume 6 Number 6 e593-e702 <a href="http://www.thelancet.com/journals/langlo/issue/current">http://www.thelancet.com/journals/langlo/issue/current</a> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Jun 2018 Volume 18 Number 6 p583-696 183-e220 <a href="http://www.thelancet.com/journals/laninf/issue/current">http://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

#### **Lancet Respiratory Medicine**

Jun 2018 Volume 6 Number 6 p403-478 e19-e27

## http://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 22, Issue 6, June 2018 <a href="https://link.springer.com/journal/10995/22/6/page/1">https://link.springer.com/journal/10995/22/6/page/1</a> [Reviewed earlier]

## **Medical Decision Making (MDM)**

Volume 38, Issue 5, July 2018 <a href="http://mdm.sagepub.com/content/current">http://mdm.sagepub.com/content/current</a> [Reviewed earlier]

## **The Milbank Quarterly**

A Multidisciplinary Journal of Population Health and Health Policy Volume 96, Issue 2 Pages: 215-408 June 2018 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

#### **Nature**

Volume 558 Issue 7710, 21 June 2018 http://www.nature.com/nature/current issue.html Editorial | 20 June 2018

## **Evidence synthesis needs greater incentives**

Enlarge and better reward efforts that examine past discoveries to set policy and agendas.

As societal challenges grow in research priority, there is ever more need for such synthesis.

But it takes effort, as described by, for example, a Cornell University Library guide to a systematic review (go.nature.com/2k6ftil). And, more problematically, the academic ecosystem does not incentivize such work.

To help nudge the system in that direction, Nature this week publishes two Comment articles that highlight the importance of such assessments of evidence, and suggest ways to maximize their effectiveness. In the first, several experts from policy, funding and publishing (including Nature's editor-in-chief) present four principles to help make evidence syntheses aimed at policymakers easier to commission, and more powerful in delivery and implementation. The second, by two researchers who focus on evidence for conservation biology, discusses a form of evidence synthesis that can provide a more cost-effective way to appraise evidence when data are sparse and patchy. This is a reflection of the reality that, for some interventions, randomized controlled trials aren't possible, but there is, nevertheless, a need to make sense of the available evidence...

Comment | 20 June 2018

## Four principles to make evidence synthesis more useful for policy

Reward the creation of analyses for policymakers that are inclusive, rigorous, transparent and accessible, urge Christl A. Donnelly and colleagues.

Christl A. Donnelly, Ian Boyd[...] & Chris Wormald.

Comment | 20 June 2018

## A fresh approach to evidence synthesis

Systematic reviews have transformed medicine, but a more cost-effective means of appraisal is needed for fields in which data are sparse and patchy, argue
William J. Sutherland and Claire F. R. Wordley.

#### **Nature Medicine**

Volume 24 Issue 6, June 2018 <a href="https://www.nature.com/nm/volumes/24/issues/6">https://www.nature.com/nm/volumes/24/issues/6</a> [Reviewed earlier]

## **Nature Reviews Immunology**

Volume 18 Issue 6, June 2018 <a href="https://www.nature.com/nri/volumes/18/issues/6">https://www.nature.com/nri/volumes/18/issues/6</a> [Reviewed earlier]

## **New England Journal of Medicine**

June 21, 2018 Vol. 378 No. 25 <a href="http://www.nejm.org/toc/nejm/medical-journal">http://www.nejm.org/toc/nejm/medical-journal</a> <a href="Perspective">Perspective</a>

## <u>Keeping Your Cool — Doing Ebola Research during an Emergency</u>

Charlotte J. Haug, M.D., Ph.D.

Two key international actors, Médecins sans Frontières (MSF, or Doctors without Borders) and the World Health Organization (WHO), are testing an Ebola vaccine during the current outbreak in the Democratic Republic of Congo (DRC), in collaboration with the ministry of health (see <a href="map">map</a>). They must act in a state of extreme uncertainty: the situation is evolving by the hour, information is hard to come by, and the ethical dilemmas and practical hurdles are abundant. And they are using slightly different approaches...

#### **Pediatrics**

June 2018, VOLUME 141 / ISSUE 6 http://pediatrics.aappublications.org/content/141/6?current-issue=y [Reviewed earlier]

#### **Pharmaceutics**

Volume 10, Issue 2 (June 2018) http://www.mdpi.com/1999-4923/10/2 [New issue; No digest content identified]

#### **PharmacoEconomics**

Volume 36, Issue 6, June 2018 <a href="https://link.springer.com/journal/40273/36/6/page/1">https://link.springer.com/journal/40273/36/6/page/1</a> [Reviewed earlier]

#### **PLOS Currents: Disasters**

http://currents.plos.org/disasters/ [Accessed 23 Jun 2018] [No new digest content identified]

#### **PLoS Currents: Outbreaks**

http://currents.plos.org/outbreaks/
[Accessed 23 Jun 2018]
[No new digest content identified]

#### **PLoS Medicine**

http://www.plosmedicine.org/ (Accessed 23 Jun 2018) [No new digest content identified]

## **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 23 Jun 2018) [No new digest content identified]

#### **PLoS One**

http://www.plosone.org/ [Accessed 23 Jun 2018] Research Article

#### Early life malaria exposure and academic performance

Ninja Ritter Klejnstrup, Julie Buhl-Wiggers, Sam Jones, John Rand Research Article | published 22 Jun 2018 PLOS ONE https://doi.org/10.1371/journal.pone.0199542

## Adverse events after vaccination among HIV-positive persons, 1990-2016

John R. Su, Carmen Ng, Paige W. Lewis, Maria V. Cano Research Article | published 19 Jun 2018 PLOS ONE https://doi.org/10.1371/journal.pone.0199229

## Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among male baccalaureate students in Hong Kong

Teris Cheung, Joseph T. F. Lau, Johnson Z. Wang, P. K. H. Mo, Y. S. Ho Research Article | published 18 Jun 2018 PLOS ONE <a href="https://doi.org/10.1371/journal.pone.0198615">https://doi.org/10.1371/journal.pone.0198615</a>

## <u>Acellular pertussis vaccines effectiveness over time: A systematic review, meta-</u> analysis and modeling study

Ayman Chit, Hossein Zivaripiran, Thomas Shin, Jason K. H. Lee, Antigona Tomovici, Denis Macina, David R. Johnson, Michael D. Decker, Jianhong Wu Research Article | published 18 Jun 2018 PLOS ONE https://doi.org/10.1371/journal.pone.0197970

## **PLoS Pathogens**

http://journals.plos.org/plospathogens/ [Accessed 23 Jun 2018] [No new digest content identified]

## PNAS - Proceedings of the National Academy of Sciences of the United States of America

http://www.pnas.org/content/early/ [Accessed 23 Jun 2018] [No new digest content identified]

## **Prehospital & Disaster Medicine**

Volume 33 - Issue 3 - June 2018 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

### **Preventive Medicine**

Volume 111 Pages 1-476 (June 2018) <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/111/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/111/suppl/C</a> [Reviewed earlier]

## **Proceedings of the Royal Society B**

16 May 2018; volume 285, issue 1878 http://rspb.royalsocietypublishing.org/content/285/1878?current-issue=y [Reviewed earlier]

#### **Public Health**

June 2018 Volume 159, p1-156 http://www.publichealthjrnl.com/current [Reviewed earlier]

#### **Public Health Ethics**

Volume 11, Issue 1, 1 April 2018

## http://phe.oxfordjournals.org/content/current [Reviewed earlier]

## **Public Health Reports**

Volume 133, Issue 3, May/June 2018 http://phr.sagepub.com/content/current [Reviewed earlier]

#### **Qualitative Health Research**

Volume 28, Issue 7, June 2018 <a href="http://qhr.sagepub.com/content/current">http://qhr.sagepub.com/content/current</a> [Reviewed earlier]

### **Research Ethics**

Volume 14, Issue 1, Jan - Mar 2018 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

### **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 23 Jun 2018] Commentary

<u>Overcoming challenges to dissemination and implementation of research findings in under-resourced countries</u>

Authors: Richard J. Derman and Frances J. Jaeger Citation: Reproductive Health 2018 15(Suppl 1):86

Published on: 22 June 2018

Abstract

Louis Pasteur once commented on the happiness that a scientist finds when, besides making a discovery, study results find practical application. Where health status is poor and resources are limited, finding such applications is a necessity, not merely a joy.

Dissemination, or the distribution of new knowledge gained through research, is essential to the ethical conduct of research. Further, when research is designed to improve health, dissemination is critical to the development of evidence-based medicine and the adoption of evidence-supported interventions and improved practice patterns within specific settings. When dissemination is lacking, research may be considered a waste of resources and a useless pursuit unable to influence positive health outcomes.

Effective translation of the findings of health research into policy and the practice of medicine has been slow in many countries considered low or lower middle-income (as defined by the World Bank). This is because such countries often have health care systems that are underresourced (e.g., lacking personnel or facilities) and thus insufficiently responsive to health needs of their populations. However, implementation research has produced many tools and strategies that can prompt more effective and timelier application of research findings to real world situations.

## Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

http://www.paho.org/journal/index.php?option=com\_content&view=featured&Itemid=101 [Reviewed earlier]

### **Risk Analysis**

Volume 38, Issue 6 Pages: 1105-1318 June 2018 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

Volume 10, 2017

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Reviewed earlier]

#### Science

22 June 2018 Vol 360, Issue 6395 http://www.sciencemag.org/current.dtl Editorial

## **Emerging stem cell ethics**

By Douglas Sipp, Megan Munsie, Jeremy Sugarman

Science22 Jun 2018: 1275

Summary

It has been 20 years since the first derivation of human embryonic stem cells. That milestone marked the start of a scientific and public fascination with stem cells, not just for their biological properties but also for their potentially transformative medical uses. The next two decades of stem cell research animated an array of bioethical debates, from the destruction of embryos to derive stem cells to the creation of human-animal hybrids. Ethical tensions related to stem cell clinical translation and regulatory policy are now center stage and a topic of global discussion this week at the International Society for Stem Cell Research (ISSCR) annual meeting in Melbourne, Australia. Care must be taken to ensure that entry of stem cell—based products into the medical marketplace does not come at too high a human or monetary price.

In Depth

#### **U.S.** center will fight infections with viruses

By Kelly Servick

Science22 Jun 2018: 1280-1281 Restricted Access

Proving ground for phage therapy will organize full clinical trials of the approach. *Summary* 

In the fight against antibiotic-resistant infections, a decades-old approach based on bacteriaslaying viruses called phages has been sidelined by technical hurdles, dogged by regulatory confusion, and largely ignored by drug developers in the West. But 2 years ago, researchers at the University of California, San Diego (UCSD), used phages to knock out an infection that nearly killed a colleague. Propelled by that success and a handful of others since, UCSD is now launching a clinical center to refine phage treatments and help companies bring them to market. The center, a first in North America, aims to be a proving ground for a treatment that has long been available in parts of Eastern Europe, but that still lacks the support of rigorous clinical trials.

#### **Science Translational Medicine**

20 June 2018 Vol 10, Issue 446 <a href="http://stm.sciencemag.org/">http://stm.sciencemag.org/</a>
[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 206 Pages 1-122 (June 2018) <a href="https://www.sciencedirect.com/journal/social-science-and-medicine/vol/206/suppl/C">https://www.sciencedirect.com/journal/social-science-and-medicine/vol/206/suppl/C</a> [Reviewed earlier]

### **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 23 Jun 2018] [No new digest content identified]

#### **Travel Medicine and Infectious Diseases**

March-April, 2018 Volume 22 <a href="http://www.travelmedicinejournal.com/">http://www.travelmedicinejournal.com/</a> [Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 23, Issue 6 Pages: i-iv, 581-690 June 2018 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### Vaccine

Volume 36, Issue 28 Pages 3993-4152 (27 June 2018) https://www.sciencedirect.com/journal/vaccine/vol/36/issue/28 Commentaries

Quadrivalent influenza vaccines in low and middle income countries: Costeffectiveness, affordability and availability

Open access Pages 3993-3997

Jan Hendriks, Raymond C.W. Hutubessy, Gary Grohmann, Guido Torelli, ... Marie-Paule Kieny

## <u>Mandatory influenza vaccination and religious accommodation for healthcare workers: Lessons from recent legal challenges</u>

Pages 3998-4000

Y. Tony Yang, Ross D. Silverman

## <u>Assessing population immunity for measles elimination – The promise and peril of serosurveys</u>

Pages 4001-4003

D.N. Durrheim, W.A. Orenstein, W.W. Schluter

## Regular Papers

## <u>Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study</u>

Original research article

Pages 4054-4061

Jessica A. Fleming, Rafael Baltrons, Elizabeth Rowley, Isabel Quintanilla, ... Niranjan Bhat

## 'What have you HEARD about the HERD?' Does education about local influenza vaccination coverage and herd immunity affect willingness to vaccinate?

Open access - Original research article

Pages 4118-4125

Jacqueline Logan, Dawn Nederhoff, Brandon Koch, Bridget Griffith, ... Nicole E. Basta

## <u>Barriers and facilitators to HPV vaccination among rural Alabama adolescents and their caregivers</u>

Original research article

Pages 4126-4133

Erin D. Boyd, Janice M. Phillips, Yu-Mei M. Schoenberger, Tina Simpson

#### **Vaccine: Development and Therapy**

https://www.dovepress.com/vaccine-development-and-therapy-archive111 (Accessed 23 Jun 2018)
[No new digest content identified]

#### Vaccines — Open Access Journal

http://www.mdpi.com/journal/vaccines (Accessed 23 Jun 2018) [No new digest content identified]

#### **Value in Health**

June 2018 Volume 21, Issue 6, p631-758 <a href="http://www.valueinhealthjournal.com/current">http://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

\* \* \* \*

## <u>From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary</u>

### **Expert Review of Vaccines**

Accepted author version posted online: 18 Jun 2018

A decade of experience with rotavirus vaccination in the United States—vaccine uptake, effectiveness, and impact

T Pindyck, JE Tate, UD Parashar

**Abstract** 

Introduction: Prior to 2006, nearly every U.S child was infected with rotavirus by 5 years of age, and rotavirus was the leading cause of severe childhood gastroenteritis. In February 2006 and June 2008, the Advisory Committee on Immunization Practices recommended a live attenuated pentavalent rotavirus vaccine (RV5) and a monovalent rotavirus vaccine (RV1), respectively, for routine vaccination of infants in the U.S.

Areas covered: We reviewed U.S. data on coverage, vaccine effectiveness (VE), and vaccine impact from 2006-2017. National rotavirus vaccine coverage estimates increased since vaccine introduction but plateaued at 71%-75% in 2013-2015, a level 15%-20% lower than that of other routine childhood vaccines. Pooled VE of full series RV5 and RV1 against rotavirus-associated hospitalizations and emergency department visits were 84% (95% CI: 80%-87%) and 83% (95% CI: 72%-89%), respectively. Vaccine introduction resulted in a median decline in rotavirus-associated hospitalizations and ED visits of 80% and 57%, respectively, along with indirect protection of unvaccinated age groups and a decrease in health care costs. A biennial pattern in rotavirus detection emerged post-vaccine implementation.

Expert Commentary: The increasing use of rotavirus vaccines has substantially diminished the burden and changed the epidemiology of rotavirus disease in US children; efforts to increase rotavirus vaccine coverage should continue.

#### **Emerging Infectious Diseases**

01 Jul 2018, 24(7):1178-1187

Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2016

A Schuchat, LJ Anderson, LE Rodewald, NJ Cox...

Abstract

The need for closer linkages between scientific and programmatic areas focused on addressing vaccine-preventable and acute respiratory infections led to establishment of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention. During its first 10 years (2006-2015), NCIRD worked with partners to improve preparedness and response to pandemic influenza and other emergent respiratory infections, provide an evidence base for addition of 7 newly recommended vaccines, and modernize vaccine distribution. Clinical tools were developed for improved conversations with parents, which helped sustain childhood immunization as a social norm. Coverage increased for vaccines to protect adolescents against pertussis, meningococcal meningitis, and human papillomavirus-associated cancers. NCIRD programs supported outbreak response for new respiratory

pathogens and oversaw response of the Centers for Disease Control and Prevention to the 2009 influenza A(H1N1) pandemic. Other national public health institutes might also find closer linkages between epidemiology, laboratory, and immunization programs useful.

\* \* \* \*

## Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

#### **The Atlantic**

http://www.theatlantic.com/magazine/ Accessed 23 Jun 2018 Health

## **How Will Trump Lead During the Next Global Pandemic? - The Atlantic**

"There is a real reason for us to be scared," President Obama's Ebola czar said. Krishnadev Calamur

The next global epidemic is likely around the corner—and no amount of U.S. retrenchment from globalization will halt that outbreak at the U.S. border.

"There is a real reason for us to be scared of the idea of facing this threat with Donald Trump in the White House," said Ron Klain, who served as President Obama's Ebola czar, at the Aspen Ideas Festival, which is cohosted by The Aspen Institute and The Atlantic. Klain said the "president is anti-science" and "trades in conspiracy theories."

"All those things would lead to the loss of many lives in the event of an epidemic in the United States where we need the public not to trade in conspiracy theories, not to believe that the news was fake, but to respect scientific expertise," said Klain, a veteran Democratic operative who served in both the Clinton and Obama administration...

#### **BBC**

http://www.bbc.co.uk/ Accessed 23 Jun 2018 [No new, unique, relevant content]

#### The Economist

http://www.economist.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

#### **Financial Times**

http://www.ft.com/home/uk Accessed 23 Jun 2018

## Salvini ramps up rhetoric with attack on mandatory vaccines

23 June 2018

Matteo Salvini, the <u>leader of Italy's far-right League</u>, has dismissed mandatory vaccinations as "useless and in many cases dangerous" as he extended a streak of provocative statements since taking power as the dominant figure of the new populist government.

In a radio interview on Friday, Mr Salvini aligned himself squarely with Italy's anti-vaccine movement, which has been fuelled by scepticism of established science and medicine. The movement was harshly critical of a law passed by the previous centre-left government requiring 10 mandatory vaccinations for school enrolment.

"We want to allow all kids to get into class, to go to school," said Mr Salvini. "We will keep going because I believe that 10 mandatory vaccinations are useless, and in many cases dangerous if not harmful."

Mr Salvini, the 45-year-old interior minister and vice-premier, has grabbed the Italian political spotlight since his new government — in <u>alliance with the anti-establishment Five Star Movement</u> — was sworn in on June 1 after a lengthy political stalemate.

Mr Salvini has developed a habit of daily, if not hourly, bombastic interventions that are challenging mainstream Italian policy and <u>setting the political agenda</u>. Mr Salvini's comments on vaccinations come after a week in which he called for a "census" of Italy's Roma population to identify anyone who should be deported, threatened to <u>remove a police escort protecting</u> <u>Roberto Saviano</u>, the anti-mafia author, and launched a barrage of attacks on non-governmental organisation <u>rescue ships saving migrants</u> in the Mediterranean Sea.

Mr Salvini's attack on vaccines is notable because it goes well beyond his ministerial remit, as well as the "contract" setting out the terms of the League's alliance in government with Five Star.

#### **Forbes**

http://www.forbes.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

### **Foreign Affairs**

http://www.foreignaffairs.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

## **Foreign Policy**

http://foreignpolicy.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

### The Guardian

http://www.guardiannews.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

#### **New Yorker**

http://www.newyorker.com/ Accessed 23 Jun 2018 [No new, unique, relevant content]

#### **New York Times**

http://www.nytimes.com/ Accessed 23 Jun 2018

### Dr. Adel Mahmoud, 76, Dies; Credited With Major Vaccines

19 June 2018

Dr. Adel Mahmoud, an infectious-disease expert who played a vital role in the development of lifesaving vaccines, died on June 11 in Manhattan. He was 76. His death, at Mount Sinai St. Luke's Hospital, was caused by a brain hemorrhage, his wife, Dr. Sally Hodder, said. As president of Merck Vaccines from 1998 until 2006, Dr. Mahmoud oversaw the creation and marketing of several vaccines that brought major advances in public health. One prevents rotavirus infection, a potentially fatal cause of diarrhea in babies. Another protects against human papillomavirus (HPV), which causes cancers of the cervix, anus, genitals and middle of the throat...

#### **Wall Street Journal**

http://online.wsj.com/home-page?\_wsjregion=na,us&\_homepage=/home/us
Accessed 23 Jun 2018
[No new, unique, relevant content]

#### **Washington Post**

http://www.washingtonpost.com/

Accessed 23 Jun 2018

Kids in these U.S. hot spots at higher risk because parents opt out of vaccinations Lena H. Sun · National/health-science · Jun 20, 2018

\* \* \*

## Think Tanks et al

## **Brookings**

http://www.brookings.edu/ Accessed 23 Jun 2018 [No new relevant content]

#### **Center for Global Development**

http://www.cgdev.org/page/press-center Accessed 23 Jun 2018 [No new relevant content]

## **CSIS**

https://www.csis.org/ Accessed 23 Jun 2018 [No new relevant content]

## **Council on Foreign Relations**

http://www.cfr.org/ Accessed 23 Jun 2018 [No new relevant content]

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<u>http://creativecommons.org/licenses/by-nc/3.0/</u>). Copyright is retained by CVEP.

CVEP is a program of the <u>GE2P2 Global Foundation</u> – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children's Hospital of Philadelphia [CHOP].

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; <u>Aeras</u>; <u>PATH</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Valera (list in formation), and the Developing Countries Vaccine Manufacturers Network (<u>DCVMN</u>).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.